This patented, next generation of cartilage therapy is designed to match biomechanical and biochemical properties of normal hyaline cartilage, restore a smooth articular cartilage surface and relieve patient symptoms and improve function.
?One of the most important ways we honor tissue donors is through our commitment to innovation,? said Thomas Cycyota, AlloSource president and CEO. ?ProChondrix provides the opportunity to both maximize the donor?s gift, while also helping recipients get their mobility back.?
Read more here.
Click here for full podcast playlist.